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ABSTRACT 
 
Hereditary Spastic Paraplegia (HSP) is a syndrome characterised by lower limb spasticity, 
occurring alone or in association with other neurological manifestations, such as cognitive 
impairment, seizures, ataxia or neuropathy.  HSP occurs worldwide, with different 
populations having different frequencies of causative genes.  The Greek population has not 
yet been characterised.  The purpose of this study was to describe the clinical presentation and 
molecular epidemiology of the largest cohort of HSP in Greece, comprising 54 patients from 
40 families. We used a targeted next generation sequencing (NGS) approach to genetically 
assess a proband from each family.  We made a genetic diagnosis in more than 50 % of cases 
and identified 11 novel variants.  Variants in SPAST and KIF5A were the most common 
causes of autosomal dominant HSP, while SPG11 and CYP7B1 were the most common cause 
of autosomal recessive HSP.  We identified a novel variant in SPG11 which led to disease 
with later onset and may be unique to the Greek population and report the first nonsense 
mutation in KIF5A.  Interestingly, the frequency of HSP mutations in the Greek population, 
which is relatively isolated, was very similar to other European populations.  We confirm that 
NGS approaches are an efficient diagnostic tool and should be employed early in the 
assessment of HSP patients. 
 
Keywords: Hereditary Spastic Paraplegia, genetics, next generation sequencing, novel 
mutations. 
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INTRODUCTION 
 
Hereditary spastic Paraplegia (HSP) refers to a heterogeneous group of disorders 
characterised by slowly progressive limb spasticity and weakness1.  Spasticity can occur in 
isolation (pure HSP), or can be complicated by additional features including learning 
disability, seizures, neuropathy or ataxia (complicated HSP).  Approximately two thirds of 
patients have a family history of the disorder, with the remainder occurring sporadically2.   
 
All modes of inheritance are known to cause HSP and at least 45 genetic types are known, 
although a smaller number of genes account for the majority of cases3.  Despite the 
abundance of genes involved in HSP, many of the genes impact on the same molecular 
pathways.  These include axonal transport (KIF5A, KIF1A), endoplasmic reticulum formation 
(ATL1, SPAST, REEP1), endosomal and lysosomal trafficking (SPG11, AP4B1), and 
mitochondrial function (SPG7, mATP6, HSPD1)2.   
 
The clinical heterogeneity of HSP and the diversity of genetic causes can make it difficult to 
achieve a genetic diagnosis in many patients.  In most clinical settings, a small number of 
genes can be sequenced by conventional Sanger methods due to the cost and low frequency of 
mutations in many genes.  Overall, more than 50 % of autosomal dominant (AD) HSP cases 
and 70 % of autosomal recessive (AR) HSP cases never receive a genetic diagnosis4.  HSP 
occurs in all populations, and there are regional variations in the frequency of causative 
genes.  However, no study has evaluated the genetic spectrum of HSP in Greece.  In this 
study we present the largest Greek cohort of HSP patients, comprising 54 patients from 40 
families. 
 
The development of massively parallel sequencing has revolutionized genetics, making it 
possible to simultaneously sequence thousands of genes, faster and at lower cost than 
traditional Sanger sequencing 5.  There are a number of different NGS technologies, including 
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whole genome, exome, targeted exome and panel based sequencing.  While sequencing a 
whole genome provides unparalleled genetic information, the interpretation of these variants 
is difficult and time consuming.  In addition, when only single probands are available for 
sequencing, genome or exome sequencing may reveal thousands of potentially pathogenic 
variants.  Targeted exome sequencing and panel based sequencing offer some advantages due 
to cost savings and the ease and speed of data interpretation. 
 
In this study, we used a combination of targeted exome sequencing and panel sequencing to 
characterise the mutational spectrum of HSP in probands from 40 Greek HSP families, 
providing insights into the genetics of HSP in this population for the first time. 
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METHODS 
 
Patient recruitment 
This study included consecutive patients referred with suspected HSP to the Neurogenetics 
Unit, 1st Department of Neurology, University of Athens Medical School, Eginition Hospital, 
over an 18-year period (1995-2013).  The Athens Neurogenetics Unit is the only unit of its 
kind in Greece and has uniquely offered molecular diagnostic testing for adult patients with 
neurogenetic disorders within the framework of the Greek public health service.  It receives 
referrals for clinical assessment and/or molecular genetic testing in patients with suspected 
neurogenetic disorders from all regions of the country.  In the case of HSP, the Unit has not 
offered diagnostic molecular testing, but has assessed patients clinically and stored DNA for 
future analysis.  Patients included in the present study originate from various regions of 
Greece, were in most cases referred by other neurologists in the Department, and gave 
informed consent for molecular genetic testing. 
 
Targeted Exome Sequencing 
Nine patients were sequenced on an Illumina Trusight Exome panel, which targets 2731 
genes known to cause human disease.  These include 34 genes associated with HSP (see 
Supplementary Table).  The complete list of targeted genes is available online from 
http://support.illumina.com/downloads/trusight_exome_product_files.html. 
DNA samples were diluted to 5 ng/μl and were then tagged and fragmented according to the 
Trusight Enrichment DNA Sample Preparation Guide.  Libraries were sequenced with an 
Illumina HiSeq 2500.  Sequences were aligned using BWA and variants called with GATK.  
Mean target coverage was 42 and 87 % of bases were read 10 times.  There was an average of 
7065 variants called per sample. 
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Truseq Custom Amplicon Panel Sequencing 
Thirty-one patients were sequenced using a custom HSP amplicon panel, which was designed 
to target the coding regions of the following genes implicated in HSP: ATL1, SPAST, BSCL2, 
HSPD1, GJC, KIAA0196, KIF5A, NIPA1, PLP, PNPLA6, REEP1, RTN2, SPG11, SPG7, 
CYP7B1, FA2H.  DNA was diluted to 250ng and procedures followed the Truseq Custom 
Amplicon Library Preparation Guide.  Libraries were sequenced on an Illumina Miseq and 
variants were called on the Illumina BaseSpace platform.  Mean coverage of the Custom 
Panel was 592 reads per targeted base.  A graphical representation of coverage per patient and 
coverage per gene may be found in Supplementary Figure 1. 
 
Sanger Sequencing  
All potentially pathogenic variants identified by next generation sequencing were confirmed 
by conventional Sanger sequencing.  The exon carrying the variant was PCR amplified using 
flanking intronic primers (primer sequences available on request).  The PCR product was 
purified and then sequenced in both directions using Big Dye Terminator version 3.1 Cycle 
Sequencing Kit (Applied Biosystems). Sequencing products were purified and read on an 
ABI 3730 DNA Analyzer (Applied Biosystems). Sequences were analysed using Seqscape 3 
software (Applied Biosystems). 
 
Variants are described with reference to the following transcripts: SPAST: NM_014946; 
NG_008730.1, KIF5A: NM_004984; NG_008155.1, REEP1: NM_001164732.1; 
NG_013037.1, ATL1: NM_015915; NG_009028.1, CYP7B1: NM_004820.3; NG_008338.1, 
SPG11: NM_025137; NG_008885.1, SPG7: NM_003119; NG_008082.1, GJC2: 
NM_020435; NG_011838.1, ZFYVE26: NM_015346; NG_011836.1.  All variants detected 
have been deposited in the Leiden Open Variation Database (LOVD) found at 
http://databases.lovd.nl/shared/genes (Patient IDs 39349 to 39359 and 46990 to 47000). 
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RESULTS 
 
Clinical Characterisation 
 
We identified 54 patients from 40 families affected by HSP. The clinical descriptions of the 
patients and families can be found in Table 1.  Thirty-six patients (67 %) presented with pure 
HSP and 18 (33 %) with complicated HSP. 
 
Pure forms:  The majority of pure HSP occurred in families with an AD mode of inheritance 
(55 %), followed by sporadic inheritance (31 %) and AR inheritance (7 %).  X-linked 
Dominant inheritance occurred in 1 family (3 %).  Just over two thirds of the patients with 
pure HSP were men.   The mean age of onset was 32 years.  The most frequent symptoms 
described in addition to spastic paraplegia were lower limb sensory disturbance (28 %) and 
urinary urgency/frequency (19 %).  Cerebellar signs and cognitive impairment occurred 
rarely.  White matter lesions on MRI were described in 3 patients. 
 
Complicated forms:  The most frequent mode of inheritance in families with a complicated 
HSP phenotype was AD (38 %), sporadic (30 %) and AR (23 %).  The mode of inheritance 
was unknown in 15 %.  There was a significant excess of men with a complicated phenotype 
(77 %) compared to women (23 %).  The mean age at onset was 23 years.   The most 
frequently reported additional symptoms were lower limb sensory disturbance (61 %), 
cognitive impairment (44 %), cerebellar signs (28 %) and neuropathy (28 %).  Urinary 
symptoms occurred in 17 %.  Three patients had thinning of the corpus callosum on MRI and 
4 patients had white matter lesions.  
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Molecular Characterisation  
 
We performed genetic analysis on one proband from each HSP family (40 total), using the 
Truseq custom HSP panel (targeting 16 of the most frequently mutated HSP genes) or 
Trusight Exome.  MLPA analysis was not performed.  This may underestimate the frequency 
of some genes due to genomic deletions. 
A genetic diagnosis was made in 6/9 patients using the Trusight Exome and 15/31 patients 
using the Truseq custom HSP panel. 
A genetic diagnosis was achieved in 13 of the 30 patients with pure HSP (43 %) and in 8 of 
the 10 patients with complicated HSP (80 %).  Where a clear AR pattern of inheritance was 
given, a genetic diagnosis could be made in all cases (5).  Single heterozygous variants found 
in known autosomal recessive HSP genes are given in Supplementary Table 1. 
 
Novel variants 
 
Of the 21 potentially pathogenic variants we identified, 11 were novel.  These are listed in 
Table 2.  These include 2 nonsense mutations in SPAST, c.430C>T & c.575T>A, and 1 in 
KIF5A c.2590C>T.  We also identified a novel frameshift mutation in SPAST, c.1591dupC. 
Of the remaining 7 novel missense variants, all but 1 are absent in available databases, 
including the ExAC browser6, the Exome Variant Server, and an internal database of over 600 
exomes.  All novel variants are predicted to be pathogenic by at least 2 in silico tools and all 
occur at conserved residues.  
 
Only the SPG11 c.5381T>C variant has a recorded frequency on control databases, with a 
reported frequency of 5 in 120,880 alleles (0.00004136) on the ExAC browser6.  No 
homozygotes have been reported.  This variant has maximally pathogenic scores on all 3 in 
silico tools and occurs at a highly conserved residue.  It occurs in combination with another 
deleterious SPG11 variant in 3 probands.  In all cases the variant occurs with a frameshift or 
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nonsense mutation and in one family, the same compound heterozygote mutations, 
c.[5470C>T]; [5381T>C]  occur in 2 affected brothers.  An unaffected brother carried only 
the c. 5381T>C variant.  For these reasons, we believe that the c. 5381T>C variant in SPG11 
may be pathogenic when it occurs in trans with another pathogenic SPG11 variant or perhaps 
in the homozygous state, and it is possible that this is a unique finding in the Greek 
population. 
 
 
Autosomal Dominant Mutations (see Table 3, Figure 1) 
 
SPAST/SPG4 
Variants in SPAST were responsible for the majority of AD HSP in our cohort.  We identified 
7 patients with potentially pathogenic variants in SPAST, of which 4 were novel and 3 
previously described as pathogenic.  The age of onset of HSP in patients with SPAST variants 
was highly variable ranging from early childhood to 50 years.  We observed a trend for an 
earlier age of onset in truncating mutations at the 5’ end of the gene (HSP62 and HSP66).  All 
but one SPAST patient had a pure HSP phenotype, although sensory disturbance was 
common.  One patient with early childhood onset had mild cognitive impairment in addition 
to spastic paraplegia (HSP66 – c.430C>T variant) and another was found to have white 
matter lesions on MRI (HSP46 – c.1536G>C variant). 
 
KIF5A 
KIF5A was the second most common AD HSP gene in our cohort.  We identified 2 patients 
with KIF5A variants, both of which were novel.  The c.2590C>T mutation is the first 
nonsense mutation identified in KIF5A to date.  Both patients presented in early childhood 
with HSP complicated by a sensorimotor axonal neuropathy, the typical phenotype of SPG10.   
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A single patient with a novel REEP1 variant and a single patient with a previously described 
pathogenic ATL1 variant were also identified. 
 
Autosomal Recessive Mutations (see Table 4, Figure 2) 
 
SPG11 
We identified 5 probands with variants in SPG11.  Two patients (HSP73 and HSP48) had a 
typical presentation of SPG11 associated HSP with a complicated phenotype, thinning of the 
corpus callosum and onset below age 20.  These patients had a novel homozygous variant, 
c.2278T>C, and 2 known pathogenic variants c.[6856C>T (;) 2030_2034del], respectively.   
 
Interestingly, the 3 patients who had the c. 5381T>C variant in SPG11 in addition to another 
deleterious variant had a significantly older age at onset.  HSP29 developed symptoms at age 
39.  He had a complicated phenotype comprising spastic paraplegia, bilateral sensorineural 
deafness, diminished vibration sensation in the upper and lower limbs and mild sensory 
axonal neuropathy on Nerve Conduction Studies.  MRI revealed mild ventricular and cortical 
sulci enlargement with diffuse periventricular T2 hyperintensity and a typical ‘ears of the 
lynx’ appearance at the frontal horn of the right lateral ventricle (see Figure 3).  We identified 
a novel nonsense mutation c.255G>A in exon 1 of SPG11 in addition to the c. 5381T>C 
variant, which we believe may be pathogenic.  DNA was not available from other family 
members to assess if these variants occurred in cis or in trans.  
 
HSP13 developed symptoms at age 60.  He had 2 affected siblings.  His parents were 
unaffected to our knowledge, implying an AR mode of inheritance.  He presented with 
progressive spastic paraplegia, hypereflexia in the upper limbs with hyporeflexia in the lower 
limbs.  There was dysdiadochokinesis.  We identified 2 variants in SPG11, a frameshift 
mutation in exon 25 (c.4307_4308del), and the c. 5381T>C variant in exon 30. 
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HSP47 had a pure HSP phenotype, and developed symptoms at age 41.  MRI revealed 
periventricular and centrum semiovale white matter lesions.  The same c.[5470C>T]; 
[5381T>C]  variants were found in the proband and her affected brother.  An unaffected 
brother carried only the c. 5381T>C variant, proving that the mutations occur in trans in these 
patients. 
 
CYP7B1 
We identified 3 probands with variants in CYP7B1/SPG5a.  One patient with a homozygous 
frameshift variant (c.250delC), had onset of spastic paraplegia at age 8 with hearing loss and 
sensory disturbance in the lower limbs.  Two siblings, who were similarly affected, were 
found to carry the same homozygous variant.  An affected sister, with onset of symptoms age 
13 years, was found to have symmetric frontoparietal white matter lesions and gaze evoked 
nystagmus.  All 3 siblings had prominent impairment of vibration sensation and an affected 
brother also had ataxia.  This finding confirms previous reports7 that mutations in CYP7B1 
may be associated with sensorineural deafness. 
 
Patient HSP45 was found to have a homozygous novel mutation in CYP7B1 (c.1322C>T). 
This patient with pure HSP had onset of symptoms at age 19.  Two siblings had later age of 
onset in the 30s and 40s, although DNA was not available for testing.   
 
Patient HSP41 was found to have the c.[1304T>C (;) 1460dupT] variants in CYP7B1.   While 
the c.1304T>C variant is novel, the c.1460dupT variant is known to cause HSP8.  This 
patient, with a pure HSP phenotype, had onset of symptoms at age 27.  Vibration and 
proprioception in the lower limbs was impaired, while imaging of the neuroaxis was normal. 
 
SPG7 
One patient (HSP16) was found to have a homozygous c.1369C>T variant in SPG7.  This 
variant has previously been reported to cause HSP in compound heterozygous state9.  This 
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patient, with onset of symptoms at age 40, was found to have mild distal upper limb 
weakness, rest tremor, lower limb sensory symptoms and mild cognitive impairment.  While 
hand tremor has been reported in up to 10 % of patients with SPG4, this is the first report of 
rest tremor occurring in a case of SPG710.  
 
X-linked mutations 
 
One patient was found to carry a small deletion in ABCD1 (c.1174_1178del: 
p.(Leu392SfsTer7), HSP4).  This patient had been reported to have a pure HSP phenotype 
with possibly dominant inheritance.  When the family history was reviewed, it was clear that 
males were affected severely, but females only mildly, and there was no male-to-male 
transmission of the disease, suggesting X-linked inheritance.  The proband had onset of 
symptoms at age 20 with progressive spastic paraplegia, urinary symptoms and sensory 
abnormalities in the lower limbs.  Brain MRI was normal and thoracic spine MRI at age 55 
revealed thinning of the thoracic spinal  Two cousins were similarly affected, and were also 
found to carry the same mutation.  After the mutation was identified, very long chain fatty 
acids (VLCFAs) were tested in the proband and found to be within the range for 
adrenoleukodystrophy (ALD).  
 
DISCUSSION 
 
In this paper we describe, for the first time, the clinical and genetic spectrum of HSP in 
Greece.  We provide a clinical description of 54 cases from 40 families.  Each of these 
families was genetically screened using a next generation sequencing approach.  We made a 
genetic diagnosis in 21 families (52.5 %).  Our cohort consisted of a heterogeneous 
population with pure and complicated, sporadic and familial HSP.   When variants in SPAST 
are excluded, our approach rendered a genetic diagnosis in 13 of 33 patients (39 %), which is 
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superior to the 25 % diagnostic rate found by Kumar et al8, who used a similar next 
generation sequencing panel to screen SPAST negative patients in Australia. 
 
Our study describes for the first time the mutational spectrum of HSP in Greece.  The 
frequency of gene mutations in HSP varies considerably across populations, therefore a 
comprehensive assessment of mutation frequency is essential to characterise the population 
and guide accurate genetic testing.  We show that point mutations in SPAST are by far the 
most common cause of AD HSP in the Greek population, which is consistent with other 
studies.  KIF5A variants were the second most common cause of AD HSP, and were the most 
frequent cause of complicated, early childhood onset HSP, consistent with previous reports 
estimating the frequency of KIF5A mutations in AD HSP at 10 % 11.  In addition, we report 
the first nonsense mutation in KIF5A (c.2590C>T) in a patient with a typical SPG10 
phenotype consisting of early onset spastic paraplegia with sensorimotor axonal neuropathy.  
To date, most pathogenic KIF5A variants have been detected in the motor domain and are 
expected to impair protein function through a dominant negative effect12.  However, 2 KIF5A 
variants outside the motor domain have been found13,14, and the mechanism with which these 
cause disease has not been identified15.  We therefore suggest that further functional work is 
required before KIF5A variants outside the motor domain can be excluded, particularly in 
patients with typical SPG10 or axonal CMT2 phenotypes. 
 
ATL1 and REEP1 were relatively rare causes of AD HSP in our population, which is 
surprising in comparison to other Western European populations.  No mutations in NIPA1 
were identified.   
 
SPG11 was the commonest cause of AR HSP, again in accordance with previous findings.  
Interestingly, we identified a novel c.5381T>C variant, which, when in combination with 
another deleterious SPG11 variant, leads to a syndrome of complicated HSP with relatively 
late onset.  This variant appears to be unique to the Greek cohort under study.  The majority 
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of SPG11 variants identified to date lead to premature protein termination or splicing defects.  
However, at least 2 missense mutations have already been identified in families with a typical 
SPG11 phenotype16,17.  Clearly further genetic and functional work will be required to 
determine if and how missense mutations in SPG11 lead to disease. 
 
CYP7B1 variants were the second most common cause of AR HSP, and we confirm that 
sensorineural deafness can occur as part of the spectrum of CYP7B1 associated HSP.   
 
Surprisingly, we identified a family with a pathogenic deletion in ABCD1 mimicking HSP 
and presenting with what was initially thought to be dominant inheritance.  It has previously 
been shown that ALD can mimic HSP and even present with an apparently autosomal 
recessive mode of inheritance18.  It is essential to identify patients with ALD as they require 
careful monitoring of adrenal function and are potentially treatable with stem cell transplant 
should cerebral ALD develop19.   
 
We did not detect potentially pathogenic variants in 19 probands.  Sixteen of these were 
sequenced using the Truseq custom HSP panel and 3 were sequenced using the Trusight 
Exome.  Of these 19, 9 had an AD family history of HSP, 8 had sporadic inheritance and the 
family history was unknown in 2.  Seventeen had a pure HSP phenotype, with only 2 patients 
having a complicated phenotype.  This raises interesting questions as to whether there are 
many more genes causing HSP that have not yet been identified.  It will be necessary to 
perform whole exome or whole genome analysis on a large cohort of phenotypically similar 
pure HSP cases to address this. 
 
This study shows that a next generation sequencing approach can be an efficient way to make 
a genetic diagnosis in a heterogeneous population naïve to genetic testing.  With one test, 
more than half of patients can be given a genetic diagnosis, allowing for resources to be 
concentrated on investigating gene negative patients and families.  NGS approaches may be 
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particularly relevant in resource poor settings, where biochemical and radiological testing 
may not be readily available or may be prohibitively expensive.  This study confirms that 
NGS approaches are efficient and cost effective and should be employed in the first line of 
investigation in HSP patients. 
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Figure Legends 
 
Figure 1. Schematic representations of the spastin, KIF5A, REEP1 and atlastin proteins.  
Novel mutations are shown in bold.  TM: Transmembrane, MIT:  Microtubule Interacting 
Domain, MTBD: Microtubule Binding Domain, AAA:  ATPase Associated with Diverse 
Cellular Activity. 
 
Figure 2.  Schematic representations of the SPG11, CYP7B1 and paraplegin proteins.  Novel 
mutations are in shown in bold.  TM: Transmembrane Domain, FtsH: Filamentous 
temperature sensitive H. 
 
Figure 3. A, B and C: axial T2 images showing diffuse periventricular hyperintensity 
(arrows), along with ventricular and cortical sulci enlargement; D:  axial FLAIR image 
showing early ‘flame-’ or ‘ears-of-the-lynx-’ formation (arrow). 
 
Supplementary Figure 1.  Barplot illustrating the mean coverage per patient (A) and per 
gene (B) obtained with the Truseq Custom Amplicon HSP panel. 
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